Biogen Inc. (BIIB) Sees Strong Trading Volume
Biogen Inc. (NASDAQ:BIIB) shares saw unusually-high trading volume on Friday . Approximately 1,463,058 shares were traded during mid-day trading, an increase of 13% from the previous session’s volume of 1,293,025 shares.The stock last traded at $313.39 and had previously closed at $306.03.
BIIB has been the topic of a number of recent analyst reports. Piper Jaffray Cos. reaffirmed a “neutral” rating on shares of Biogen in a research report on Wednesday, August 3rd. Morgan Stanley upped their target price on Biogen from $383.00 to $385.00 and gave the company an “overweight” rating in a research report on Thursday, July 21st. Jefferies Group reaffirmed a “buy” rating and issued a $317.00 target price on shares of Biogen in a research report on Wednesday, July 13th. Credit Suisse Group AG reaffirmed a “hold” rating and issued a $312.00 target price on shares of Biogen in a research report on Friday, July 22nd. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $287.00 target price on shares of Biogen in a research report on Sunday, July 24th. Ten analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $345.89.
The firm has a market capitalization of $68.71 billion and a PE ratio of 18.32. The stock has a 50 day moving average of $302.07 and a 200 day moving average of $271.44.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.69 by $0.52. During the same quarter in the previous year, the firm posted $4.22 EPS. The business earned $2.89 billion during the quarter, compared to the consensus estimate of $2.79 billion. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, analysts predict that Biogen Inc. will post $20.11 earnings per share for the current year.
In other news, CEO George A. Scangos sold 157 shares of Biogen stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $280.00, for a total value of $43,960.00. Following the completion of the sale, the chief executive officer now directly owns 54,779 shares of the company’s stock, valued at approximately $15,338,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Adam Koppel sold 555 shares of Biogen stock in a transaction on Monday, June 6th. The shares were sold at an average price of $290.00, for a total value of $160,950.00. Following the completion of the sale, the executive vice president now directly owns 2,402 shares of the company’s stock, valued at $696,580. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Biogen stock. US Bancorp DE boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 3.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 71,143 shares of the biotechnology company’s stock after buying an additional 2,076 shares during the period. US Bancorp DE’s holdings in Biogen were worth $21,793,000 at the end of the most recent quarter.
Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.